ATE534736T1 - Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen - Google Patents
Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungenInfo
- Publication number
- ATE534736T1 ATE534736T1 AT05774134T AT05774134T ATE534736T1 AT E534736 T1 ATE534736 T1 AT E534736T1 AT 05774134 T AT05774134 T AT 05774134T AT 05774134 T AT05774134 T AT 05774134T AT E534736 T1 ATE534736 T1 AT E534736T1
- Authority
- AT
- Austria
- Prior art keywords
- degenerative
- compounds
- treatment
- inflammatory diseases
- identification methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003412 degenerative effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 210000002744 extracellular matrix Anatomy 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57930704P | 2004-06-14 | 2004-06-14 | |
| PCT/EP2005/052754 WO2005121778A2 (en) | 2004-06-14 | 2005-06-14 | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE534736T1 true ATE534736T1 (de) | 2011-12-15 |
Family
ID=35503767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05774134T ATE534736T1 (de) | 2004-06-14 | 2005-06-14 | Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7306923B2 (de) |
| EP (4) | EP2256198A1 (de) |
| JP (1) | JP2008502355A (de) |
| AT (1) | ATE534736T1 (de) |
| CA (1) | CA2569511A1 (de) |
| MX (1) | MXPA06014577A (de) |
| WO (1) | WO2005121778A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7485468B2 (en) * | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
| CN101479377A (zh) * | 2005-12-22 | 2009-07-08 | 简·恩尼斯 | 来自冷冻的脐带组织的活细胞 |
| EP2162747B1 (de) | 2007-06-20 | 2014-04-30 | Galapagos N.V. | Molekulaire targets und verfahren zur identifikation von substanzen für die behandlung von degenerativen knochen- und gelenkserkrankungen |
| TW200918099A (en) | 2007-09-14 | 2009-05-01 | Nitto Denko Corp | Drug carriers |
| US8450397B2 (en) * | 2007-09-25 | 2013-05-28 | Dunlop Sports Co. Ltd. | Golf ball |
| DE102007059839A1 (de) | 2007-12-11 | 2009-06-25 | Harald Dipl.-Ing. Feuerherm | Schlauchförmiger Vorformling und Herstellung blasgeformter Teile und Verfahren sowie Vorrichtung zur Herstellung des Vorformlings |
| EP2789626B1 (de) | 2008-09-24 | 2018-07-18 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Peptide und Zusammensetzungen zur Prävention von Zellenadhäsion und Verfahren zu deren Verwendung |
| JP5758302B2 (ja) | 2008-12-29 | 2015-08-05 | テル ハショメール メディカル リサーチ，インフラストラクチャ アンド サービシーズ リミテッド | 細胞接着の防止のためのペプチド及び組成物、並びにこれらの使用方法 |
| AU2015224504B2 (en) * | 2008-12-29 | 2018-02-22 | Tel Hashomer Medical Research, Infrastructure And Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
| US11174299B2 (en) | 2008-12-29 | 2021-11-16 | Dispersebio Ltd. | Peptides and compositions for prevention of cell adhesion and methods of using same |
| WO2010115841A1 (en) * | 2009-04-01 | 2010-10-14 | Galapagos Nv | Methods and means for treatment of osteoarthritis |
| WO2013119853A1 (en) | 2012-02-07 | 2013-08-15 | La Jolla Institute For Allergy And Immunology | Epitopes from allergen proteins and methods and uses for immune response modulation |
| WO2014153118A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| WO2019054922A1 (en) * | 2017-09-13 | 2019-03-21 | Alexera Ab | METHODS OF IDENTIFYING THERAPEUTIC AGENTS THAT INTERACT WITH STK24 |
| CN115190804A (zh) * | 2020-01-14 | 2022-10-14 | 纽约市哥伦比亚大学理事会 | 通过重定向内源性去泛素化酶稳定靶向蛋白质的组合物和方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU4769893A (en) | 1992-07-17 | 1994-02-14 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| WO2000014250A1 (en) | 1998-09-09 | 2000-03-16 | The Board Of Regents Of The University Of Oklahoma | Tyrosylprotein sulfotransferase polypeptides and polynucleotides |
| EP1051499A2 (de) | 1998-01-29 | 2000-11-15 | The Board of Regents of the University of Oklahoma | Tyrosylprotein-sulfotransferase polypeptide und polynucleotide |
| US6538173B2 (en) * | 1998-02-13 | 2003-03-25 | The Wistar Institute | Compositions and methods for wound healing |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US20020151681A1 (en) * | 1999-03-12 | 2002-10-17 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| US20050112118A1 (en) * | 1999-12-02 | 2005-05-26 | Myriad Genetics, Incorporated | Compositions and methods for treating inflammatory disorders |
| US7332337B2 (en) | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
| DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
| US20020132823A1 (en) | 2001-01-17 | 2002-09-19 | Jiahuai Han | Assay method |
| AU2002253104A1 (en) | 2001-03-07 | 2002-09-19 | Galapagos Genomics B.V. | Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds |
| US6537780B2 (en) | 2001-03-28 | 2003-03-25 | Applera Corporation | Isolated nucleic acid molecules encoding transferase enzymes |
| US6426221B1 (en) * | 2001-08-01 | 2002-07-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of RIP2 expression |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| AU2003225535A1 (en) * | 2002-01-31 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
| AU2003291625B2 (en) * | 2002-09-16 | 2009-10-08 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| WO2004041170A2 (en) * | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1588163A2 (de) * | 2003-01-23 | 2005-10-26 | Eirx Therapeutics Ltd | Kinasen und g-protein gekoppelte rezeptoren die in der apoptose involviert sind |
| US20060188885A1 (en) * | 2003-04-18 | 2006-08-24 | Bodian Dale L | High throughput functional genomic screening methods for osteoarthritis |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| DE10328033A1 (de) | 2003-06-19 | 2005-01-05 | Bläß, Stefan, Dr. | Verfahren und ArthritisChip zur Diagnostik, Verlaufskontrolle sowie zur Charakterisierung der rheumatoiden Arthritis und der Osteoarthrose |
| US20070105114A1 (en) * | 2003-07-29 | 2007-05-10 | Martha Li | Biomarkers of cyclin-dependent kinase modulation |
| US7485468B2 (en) * | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
-
2005
- 2005-06-14 EP EP10174544A patent/EP2256198A1/de not_active Withdrawn
- 2005-06-14 US US11/152,366 patent/US7306923B2/en not_active Expired - Fee Related
- 2005-06-14 EP EP10174541A patent/EP2270160A1/de not_active Withdrawn
- 2005-06-14 CA CA002569511A patent/CA2569511A1/en not_active Abandoned
- 2005-06-14 EP EP05774134A patent/EP1773997B1/de not_active Not-in-force
- 2005-06-14 MX MXPA06014577A patent/MXPA06014577A/es active IP Right Grant
- 2005-06-14 EP EP10174539A patent/EP2256197A1/de not_active Withdrawn
- 2005-06-14 JP JP2007526437A patent/JP2008502355A/ja active Pending
- 2005-06-14 WO PCT/EP2005/052754 patent/WO2005121778A2/en not_active Application Discontinuation
- 2005-06-14 AT AT05774134T patent/ATE534736T1/de active
-
2007
- 2007-09-12 US US11/854,037 patent/US7919259B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,142 patent/US20110118140A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090062137A1 (en) | 2009-03-05 |
| CA2569511A1 (en) | 2005-12-22 |
| EP1773997B1 (de) | 2011-11-23 |
| EP1773997A2 (de) | 2007-04-18 |
| JP2008502355A (ja) | 2008-01-31 |
| MXPA06014577A (es) | 2007-03-23 |
| US7919259B2 (en) | 2011-04-05 |
| US20060014184A1 (en) | 2006-01-19 |
| EP2256198A1 (de) | 2010-12-01 |
| US20110118140A1 (en) | 2011-05-19 |
| EP2256197A1 (de) | 2010-12-01 |
| US7306923B2 (en) | 2007-12-11 |
| WO2005121778A2 (en) | 2005-12-22 |
| WO2005121778B1 (en) | 2007-02-01 |
| WO2005121778A3 (en) | 2006-11-23 |
| EP2270160A1 (de) | 2011-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE534736T1 (de) | Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| DOP2005000040A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| DE602004029580D1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| UY28450A1 (es) | Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos. | |
| BRPI0415288A (pt) | composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto | |
| BRPI0610644B8 (pt) | composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. | |
| BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
| UY28484A1 (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
| TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture | |
| ATE437861T1 (de) | 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| ECSP066888A (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos | |
| MX2009012525A (es) | Pirazol-pirrolidinas como inhibidores de gamma secretasa. | |
| BR0315462A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação | |
| DE60326069D1 (de) | 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen | |
| ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
| UY29806A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurológicos | |
| UY28458A1 (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos | |
| DE602005007912D1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| ATE478707T1 (de) | Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen | |
| BRPI0509559A (pt) | compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos |